Johanna Sistonen
Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.
Kummer D, Froehlich T, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr C. Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics 2015; 16:1367-77.
05.08.2015Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.
05.08.2015Pharmacogenomics 2015; 16:1367-77
Kummer Dominic, Froehlich Tanja K, Joerger Markus, Aebi Stefan, Sistonen Johanna, Amstutz Ursula, Largiadèr Carlo R
Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
Amstutz U, Offer S, Sistonen J, Joerger M, Diasio R, Largiadèr C. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clin Cancer Res 2015; 21:2038-44.
05.02.2015Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
05.02.2015Clin Cancer Res 2015; 21:2038-44
Amstutz Ursula, Offer Steven M, Sistonen Johanna, Joerger Markus, Diasio Robert B, Largiadèr Carlo R
Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
Büchel B, Sistonen J, Jörger M, Aebi Y, Schürch S, Largiadèr C. Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients. Clin Chem Lab Med 2013; 51:1681-8.
01.08.2013Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
01.08.2013Clin Chem Lab Med 2013; 51:1681-8
Büchel Barbara, Sistonen Johanna, Jörger Markus, Aebi Yolanda, Schürch Stefan, Largiadèr Carlo R